Nos publications
Compritol® 888 ATO: a sustained release lipid matrix for once a day aceclofenac tablets
AAPS Annual Meeting & Exposition – Denver (USA) - nov 2017
Compritol® 888 ATO: a sustained release lipid matrix for once a day aceclofenac tablets
AAPS Annual Meeting & Exposition – Denver (USA) - nov 2016
Impact of hot and wet granulation techniques on Compritol® 888 ATO lipid matrices for extended release of highly water soluble high dose API
CRS Annual Meeting – Seattle (2016) - 2016
The poster describes the formulation of sustained release tablets with Metformin HCl (a well-known oral antihyperglycemic) using Compritol® 888 ATO as a sustained release agent. Different granulation techniques were evaluated to elucidate the impact of formulation and process on tablet properties and drug release. The objective was to determine a simple process that enables the production of ‘smaller’ tablets, using less excipients, whilst maintaining therapeutic drug dose and obtaining drug release which passes Pharmacopeial specifications.
Influence of Formulation Factors and Compression Force on Release Profile of Sustained Release Metoprolol Tablets using Compritol® 888 ATO as Lipid Excipient
Indian J Pharm Sci 2015;77(5): 620-625 - sep 2015
Release profile of metoprolol from sustained release tablets using Compritol® 888 ATO as SR lipid matrix agent showed high reliability. Different sources of active ingredient and batches of Compritol® were evaluated at different compression forces and in dissolution media containing or not ethanol. The formulation appeared to be very robust and is not affected by these variables. Therefore Compritol® offers great potential in the formulation of reliable SR tablets.
New insights into the stability of SR lipid matrix tablets
CRS Annual Meeting – Edinburgh (Scotland) - jui 2015
Optimizing a wet granulation process to obtain high-dose sustained-release tablets with Compritol® 888 ATO.
Drug Development and Industrial Pharmacy, Volume 41 - Issue 10 https://doi.org/10.3109/03639045.2014.1002410 - fév 2015
This study demonstrates how a wet granulation with Compritol® 888 is an effective approach to improve material flow and compressibility. High-dose lipid matrix tablets with sustained release profiles were successfully produced.
Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction
Journal of Controlled Release, Volume 197, Pages 158-164 https://doi.org/10.1016/j.jconrel.2014.11.013 - jan 2015
Solid lipid excipients: born to be extruded!
nov 2014
Functional excipients are critical to the successful application of HME to resolve formulation challenges. Whilst polymers show potential in both controlled release and in improving the solubility and dissolution of poorly soluble compounds they are not ideal materials for extrusion. Lipid excipients are distinctly different to polymers and behave differently in HME. This article highlights two glyceride-esters: Compritol® 888 ATO and Precirol® ATO 5. They melt at relatively low temperatures and recrystallize quickly. They extrude well and can produce strand-like extrudates which can be down streamed into powders or granules.
These glyceride-esters can be used as release retarding agents/dissolution modifiers for both insoluble and soluble drugs even for high drug loading. In combination with plastic polymers they also can act as plasticizer/processing aid enabling lower temperature process and continuous production.
At Gattefossé we aim to share our knowledge to help formulators use lipid excipients to their best advantage.
Compritol® 888 ATO vs Precirol® ATO 5 in hot melt extrusion: investigation of operating window limits
AAPS Annual Meeting and Exposition – San Diego (USA) - nov 2014